Schering Corporation

Other

Robert W Watkins

Bernard R Neustadt

David R Andrews

Paul E McNamara

Ronald J Doll

Elizabeth M Smith

Elijah H Gold

Charles V Magatti

Federico C Gaeta

David J Blythin

Karen R Jackson

An electron block frame pouring fixture, and a method of using the fixture, the fixture including a base member having a recessed portion surrounded on each side, the recessed portion configured to receive an electron block frame therein, and a plurality of clamp members connected to the base member proximate each of the respective sides of the recessed portion, the clamp members being configured to be selectively actuated to press a received electron block frame downward into the recessed portion, wherein the recessed portion is configured to prevent lateral movement of the received electron block frame.

Electron block frame pouring fixture

Certain exemplary embodiments can provide a method comprising, via a signal, triggering an illumination of a first light source and a second light source, the first light source adapted to lighten a first image, the second light source adapted to lighten a second image, the first image rendered side-by-side with the second image.

Systems, devices, and/or methods for viewing images

The present invention relates to ophthalmo-logical pharmaceutical compositions comprising a renin inhibitor and to methods for using said composition in the treatment of glaucoma.

Antiglaucoma compositions and methods

The present invention relates to ophthalmological pharmaceutical compositions comprising a renin inhibitor and to methods for using said composition in the treatment of glaucoma.

A method and composition for reducing and/or controlling elevated intraocular pressure, especially the elevated intraocular pressure associated with glaucoma, are disclosed in which an angiotensin II antagonist is administered to the eye.

Angiotensin II receptor blockers as antiglaucoma agents

Color selection chart

Methods and pharmaceutical compositions are disclosed for reducing intraocular pressure. The methods and compositions employ an active ingredient which comprises certain benzothiadiazinyl and quinazolinyl substituted carboxyalkyl dipeptides wherein the benzothiadiazinyl or quinazolinyl portions are joined to the dipeptide portions by an aminocarbonyl group.

Carboxyalkyl dipeptides as antiglaucoma agents

Pharmaceutical compositions and a method for reducing intraocular pressure by topically applying a carboxyalkyl dipeptide are disclosed.

Antiglaucoma agents

The use of an angiotensin converting enzyme inhibitor for reducing and controlling the elevation of intraocular pressure associated with the use of corticosteroids is disclosed. Also disclosed are the use of the combination of an angiotensin converting enzyme inhibitor and a steroid, and pharmaceutical compositions comprising the combination.

Ophthalmic compositions

The present invention relates to ophthalmological pharmaceutical compositions comprising (benzothiadiazine, benzamide and benzenesulfonyl)phenyl-substituted carboxyalkyl dipeptide compounds and to methods for using said composition in reducing intraocular pressure, e.g., in the treatment of glaucoma.

A method for reducing intraocular pressure by topically applying 7-{N-[1(S)-Carboxy-3-phenylpropyl]-(S)-alanyl}-1,4-dithia-7-azaspiro[4.4]n onane-8(S)-carboxylic acid is disclosed.

Growing community of inventors

Great Meadows, NJ, United States of America

Robert W Watkins